en · de · es
sr9009-notes.peptides8425.com › Faq › Mechanism And Preclinical Findings — Field Notes

Mechanism And Preclinical Findings — Field Notes

By Editorial Desk · published 2026-03-22 · last reviewed 2026-04-14 · Faq

Everything below concerns bioavailability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Related pages on this site

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Reference notes

=== United States === Prominent outdoor retailers in the United States include Dick's Sporting Goods, Eddie Bauer, Backcountry.com, Outdoor Voices, REI, Patagonia, Marmot, Moosejaw, Sierra, The North Face and L.L.Bean.

== History == Mestanolone was first synthesized in 1935 along with methyltestosterone and methandriol. It was developed by Roussel in the 1950s and was introduced for medical use, under the brand names Androstalone and Ermalone, by at least 1960. It was marketed in Germany. The drug was originally thought to be a potent anabolic agent, but subsequent research showed that it actually has relatively weak anabolic effects and is mostly an androgen. Mestanolone was used as a doping agent in athletes competing in the Olympics from East Germany due to a state-sponsored doping program in the 1970s and 1980s. Its value is said to have been less as a muscle-builder and more as an androgen in the central nervous system and neuromuscular interaction, improving speed, strength, aggression, focus, endurance, and stress resilience. Today, mestanolone has mostly been discontinued in medicine, though it is still available in Japan.

In response, Rose hit the boy over the head with the bowl, then repeatedly kicked him in the head and chest as she shouted, "You did that on purpose, you little swine!" On another occasion Rose became furious about a missing kitchen utensil, grabbed a knife she had been using to cut a slab of meat, and repeatedly inflicted abrasions to Mae June's chest until her rib cage was covered with light knife wounds. All the while Mae screamed, "No, Mum! No, Mum!" as Heather and Stephen stood by, sobbing helplessly. Even Fred was a sporadic victim of his wife's violence. On one occasion in August 1974 Rose pursued Fred with a carving knife in her hand. Fred was able to run into a different room and slam the door shut behind himself as Rose lunged at him with the knife. The knife embedded itself in the door, and Rose's hand slid down the blade, almost severing three fingers. In response, Rose calmly wrapped her hand in a towel and said, "Look what you done, fella. You've got to take me to the hospital now."

Sources: en.wikipedia.org

Reference notes

Some investigators have attributed the onset of puberty to a resonance of oscillators in the brain. By this mechanism, the gonadotropin pulses that occur primarily at night just before puberty represent beats. An array of "autoamplification processes" increases the production of all of the pubertal hormones of the hypothalamus, pituitary, and gonads.

== Registration of PKMM rejected == In 1950, the Federation of Malaya Government rejected the registration of the Malay Nationalist Party of Malaya (Parti Kebangsaan Melayu Malaya, PKMM) as a legitimate political party. PKMM had two wings, namely Angkatan Pemuda Insaf and Angkatan Wanita Sedar. Initially, PKMM did not have communist leanings. After Mokhtaruddin Lasso was elected as the first PKMM president in October 1946, this party was influenced with communism. The Young Malays Union (Kesatuan Melayu Muda, KMM) merged with PKMM, and Burhanuddin al-Helmy became the second PKMM president. Burhanuddin led PKMM toward the formation of Melayu Raya, a merger of Indonesia and Malaya. In December 1947, Ishak Haji Mohamed became the third PKMM president and PKMM switched from communism to nationalism. PKMM tended against United Malays National Organisation (UMNO) and colonisation. PKKM established the Pusat Tenaga Rakyat (PUTERA), a conglomeration of radical Malay Political Parties and then merged with the All-Malaya Council of Joint Action (AMCJA) which thoroughly opposed the 1948 Federation Agreement for the foundation of the Federation of Malaya. PKMM accused officials selected in the Federation of Malaya of being "puppets" of the "Colonial Office". For PKMM, there was no basis in "preparing Malaya as a democratic government".

Prodigiosin is a red dye produced by many strains of the bacterium Serratia marcescens, as well as other Gram-negative, gamma proteobacteria such as Vibrio psychroerythrus and Hahella chejuensis. It is responsible for the pink tint occasionally found in grime that accumulates on porcelain surfaces such as bathtubs, sinks, tiles and toilet bowls. It is in the prodiginine family of compounds which are produced in some Gram-negative gamma proteobacteria, as well as select Gram-positive Actinobacteria (e.g. Streptomyces coelicolor). The name prodigiosin is derived from prodigious (i.e. something marvelous).

Sources: en.wikipedia.org

Notes from published material

As a consequence, the female-specific diversity of our genome would fit less well with geography and linguistics than would our male-specific component. [...] If that were to prove to be the case, then the common belief that we speak our mother's tongue should be revised in favor of the concept of a 'father's tongue'. Estella Poloni also presented the Father Tongue hypothesis at an international conference in Paris in April 2000. On the basis of this population genetic work, the Dutch historical linguist George van Driem elaborated the Father Tongue hypothesis in his ethnolinguistic publications and in population genetic publications which he has co-authored. At the Indo-Pacific Prehistory Association conference in Taipei in 2002 he proposed that

=== OXGR1 receptor-dependent bioactions === OXGR1 (also known as GPR99) is a G protein-coupled receptor, i.e., a receptor located on the surface membrane of cells that binds certain ligands and is thereby stimulated to activate G proteins that elicit pre-programmed responses in their parent cells. OXGR1 was identified as a receptor for: a) α-ketoglutarate in 2004; b) three leukotrienes viz., leukotrienes E4, C4, and D4 in 2013. and c) itaconate in 2023. These ligands have the following relative potencies in stimulating responses in OXGR1-bearing cells (Note that LTE4 can stimulate OXGR1 at concentrations far lower than those of the other four ligands):

February 6: Law modifying the rules for legal separation. July 15: Law on free medical assistance for people without means: women giving birth are considered equivalent to sick persons. August 19: A law concerning fire safety measures in certain regions of France holds the husband civilly liable for offenses and violations committed by his wife. July 20, 1895: Law on savings banks. December 7, 1897: Law granting women the right to be witnesses in civil status acts and in official documents in general. 1898

=== Mary Conner === Mary Conner is played by Jayden Rey. Mary is D.J. and Geena's daughter. Mary is named after her deceased great-great-grandmother, Nana Mary. In Season 3, D.J. begins a new job requiring him to work long hours and often in neighboring towns. Although Geena and D.J.'s friends are checking on her throughout the day, Mary tells Darlene she is lonely. Darlene and Becky decide to have her live at the Conner house during the week without first asking D.J. He is initially angry, but relents when Mary says she wants to stay.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network